Streetbeat News

DYAI

Dyadic International, Inc.

https://www.dyadic.com

Industry

Biotechnology

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Open

1.07

Mkt cap

34M

Volume

13K

High

1.15

P/E Ratio

-3.93

52-wk high

2.67

Low

1.07

Div yield

N/A

52-wk low

0.93

Dyadic International (NASDAQ:DYAI) is scheduled to release its quarterly earnings report on Thursday, 2024-03-28, with an expected EPS of $-0.06. Investors are hopeful for a beat on this estimate and positive guidance for future growth. Historical data shows mixed reactions to past earnings reports, with share price movements ranging from a 20% increase to a 5% decrease following earnings announcements.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 4:01 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. TC BioPharm, Dyadic International, and Mesoblast were among the top gainers, with shares increasing by 74.5%, 21.73%, and 19.53% respectively. On the losing end, Ainos, Nexalin Technology, and Fortrea Holdings saw their shares fall by 15.6%, 11.64%, and 10.32% respectively. These movements reflect the dynamic nature of the healthcare stock market, influenced by factors such as quarterly earnings reports.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 1:06 pm

Dyadic International, Inc. (NASDAQ:DYAI) has announced a strategic partnership with Rabian BV to develop affordable rabies vaccines using its C1 protein production platform. The collaboration, supported by Eurostars and the European Union's Horizon Europe, aims to address the global rabies burden, particularly in lower- and middle-income countries. Dyadic will receive an equity stake, fully funded R&D costs, and royalties upon commercialization. This partnership builds on a long-standing collaboration between the two entities, focusing on making preventive vaccination more accessible and cost-effective.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:37 pm

Dyadic International, Inc. has progressed its collaboration with the Israel Institute for Biological Research, focusing on developing solutions for bio-threats and emerging diseases. This partnership aims to leverage Dyadic's proprietary C1 gene expression platform to accelerate the development and production of biopharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:33 pm

In Monday's after-market session, several health care stocks showed significant movement. Trxade Health (MEDS) saw a notable increase of 105.3%, while Universe Pharmaceuticals (UPC) experienced a significant decrease of 27.6%. Other stocks such as Iovance Biotherapeutics (IOVA) and Virpax Pharmaceuticals (VRPX) also saw upward movements, whereas companies like Sientra (SIEN) and Femasys (FEMY) faced declines.

Portfolio Pulse from Benzinga Insights

February 19, 2024 | 9:30 pm

In Friday's after-market session, several health care stocks showed notable movements. Virpax Pharmaceuticals, Dyadic International, Annovis Bio, Sagimet Biosciences, Motus GI Holdings, and ProKidney experienced gains, with increases ranging from 6.99% to 13.3%. Conversely, Universe Pharmaceuticals, Equillium, Kazia Therapeutics, Bright Green, Lucy Scientific Discovery, and NextCure saw declines, with decreases ranging from 6.85% to 21.6%. These movements reflect significant volatility in the health care sector.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 9:31 pm

Dyadic International, Inc. has partnered with Cygnus Technologies to leverage the newly developed C1 HCP ELISA Kit, which will now be available to both Dyadic and Cygnus customers. This collaboration aims to enhance the biopharmaceutical development process by providing a crucial tool for the efficient and accurate measurement of host cell proteins, a critical aspect of biologic drug development.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 1:41 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Adial Pharmaceuticals (ADIL) saw a 30.5% increase in shares to $2.78, while Dyadic International (DYAI) rose by 9.35% to $1.87. AcelRx Pharmaceuticals (ACRX) shares went up by 9.34% to $0.75, Quoin Pharmaceuticals (QNRX) increased by 9.33% to $4.8, and Revelation Biosciences (REVB) rose by 9.2% to $0.8. NexImmune (NEXI) also saw a rise of 9.03% to $1.81. On the losing side, China Pharma Holding (CPHI) shares fell by 10.6% to $0.12, Vivos Therapeutics (VVOS) declined by 9.76% to $37.0, Altamira Therapeutics (CYTO) dropped by 8.23% to $0.59, Kintara Therapeutics (KTRA) decreased by 6.33% to $0.37, Addex Therapeutics (ADXN) fell by 6.2% to $5.3 following their Q3 earnings report, and LumiraDx (LMDX) went down by 5.88% to $0.11.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 9:31 pm

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Dyadic International (NASDAQ:DYAI) and maintained a price target of $6. The reaffirmation of the Buy rating and price target suggests a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:50 pm

Dyadic International (NASDAQ:DYAI) reported its Q3 earnings, beating estimated earnings by 14.29% with an EPS of $-0.06 versus an estimate of $-0.07. However, revenue was down $482 thousand from the same period last year. Last quarter, the company missed on EPS by $0.02, which was followed by a 10.0% increase in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 9:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.